| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | AZD6244 | UHNBreast | pan-cancer | AAC | 0.57 | 0.04 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.04 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.04 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.06 |